Literature DB >> 16041599

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

Rafael de la Torre1, Magí Farré, Brian O Mathúna, Pere N Roset, Neus Pizarro, Mireia Segura, Marta Torrens, Jordi Ortuño, Mitona Pujadas, Jordi Camí.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16041599     DOI： 10.1007/s00228-005-0965-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  16 in total

1.  Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy").

Authors:  Shaun L Greene; Paul I Dargan; Niall O'connor; Alison L Jones; Mary Kerins
Journal:  Am J Emerg Med       Date:  2003-03       Impact factor: 2.469

2.  3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.

Authors:  M Segura; J Ortuño; M Farré; J A McLure; M Pujadas; N Pizarro; A Llebaria; J Joglar; P N Roset; J Segura; R de La Torre
Journal:  Chem Res Toxicol       Date:  2001-09       Impact factor: 3.739

3.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

4.  Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?

Authors:  Euphrosyne Gouzoulis-Mayfrank; Steffanie Becker; Susanne Pelz; Frank Tuchtenhagen; Jörg Daumann
Journal:  Biol Psychiatry       Date:  2002-05-01       Impact factor: 13.382

5.  Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.

Authors:  Douglas C Jones; Christine Duvauchelle; Aiko Ikegami; Christopher M Olsen; Serrine S Lau; Rafael de la Torre; Terrence J Monks
Journal:  J Pharmacol Exp Ther       Date:  2005-01-05       Impact factor: 4.030

6.  The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus.

Authors:  Mary L Forsling; John K Fallon; Darshna Shah; Gary S Tilbrook; David A Cowan; Andrew T Kicman; Andrew J Hutt
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

8.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

9.  Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.

Authors:  V M Steen; O A Andreassen; A K Daly; T Tefre; A L Børresen; J R Idle; A K Gulbrandsen
Journal:  Pharmacogenetics       Date:  1995-08

10.  The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Authors:  M I Colado; J L Williams; A R Green
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739
View more
  14 in total

1.  Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Authors:  A M Peiró; M Farré; P N Roset; M Carbó; M Pujadas; M Torrens; J Camí; R de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

2.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

3.  Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Authors:  Samanta Yubero-Lahoz; Ricardo Pardo; Magí Farré; Brian O'Mahony; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Marcel Lí Carbó; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

4.  Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Katherine M Keyes; Silvia S Martins; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2008-06-03       Impact factor: 4.492

5.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

Review 6.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

7.  Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity.

Authors:  Joseph M Herndon; Aram B Cholanians; Lucina E Lizarraga; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2014-03-03       Impact factor: 4.849

8.  Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies.

Authors:  Erich Studerus; Patrick Vizeli; Samuel Harder; Laura Ley; Matthias E Liechti
Journal:  J Psychopharmacol       Date:  2021-03-30       Impact factor: 4.153

9.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

Authors:  Rafael de la Torre; Samanta Yubero-Lahoz; Ricardo Pardo-Lozano; Magí Farré
Journal:  Front Genet       Date:  2012-11-12       Impact factor: 4.599

10.  Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).

Authors:  Ricardo Pardo-Lozano; Magí Farré; Samanta Yubero-Lahoz; Brian O'Mathúna; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Klaus Langohr; Elisabet Cuyàs; Marcel lí Carbó; Rafael de la Torre
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.